Explore the words cloud of the MIRASYS project. It provides you a very rough idea of what is the project "MIRASYS" about.
The following table provides information about the project.
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
|Coordinator Country||Netherlands [NL]|
|Total cost||149˙190 €|
|EC max contribution||149˙190 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2016-01-01 to 2017-06-30|
Take a look of project's partnership.
|1||UNIVERSITAIR MEDISCH CENTRUM UTRECHT||NL (UTRECHT)||coordinator||149˙190.00|
Systemic sclerosis (SSc) is a life-threatening autoimmune connective tissue disorder of unknown cause, characterised by fibrosis of the skin and internal organs. SSc affects approximately 160.000 patients worldwide and is associated with life-long burden of disease. Early detection of SSc is currently impossible as diagnosis is typically based on a combination of late-stage clinical symptoms. Current diagnostics, however, are based on late clinical manifestations. There is a need for actionable biomarkers for early-stage diagnosis and disease monitoring.
Based on proprietary ERC research specific microRNA (miRNA) profiles were found that positively correlates with clinical progression and complications of SSc. Its expression was elevated in subjects who demonstrated symptoms that can precede SSc onset by years. These findings provide strong support for the prognostic and diagnostic properties of the miRNA panel in SSc.
MIRASYS has been designed to accelerate the commercialisation of a panel of highly potent miRNAs that have breakthrough diagnostic potential in SSc. MIRASYS will be used to validate these findings by setting miRNA expression level boundaries for SSc development and to incorporate these in a diagnostic assay. MIRASYS will also assess the commercial feasibility of setting-up a dedicated spin-off company to commercialise the technology. The team has analysed the IP landscape for similar approaches for SSc and no prior art on the specific miRNAs was found. In the MIRASYS ERC PoC Grant, the team will further investigate the IP position and formulate a strong IP strategy including the steps towards full Freedom to Operate.
The MIRASYS team consists of experienced science and business professionals. The team has developed several business models which need to be assessed thoroughly through in-depth market research. The results need to be consolidated into a strong business plan that will be presented to investors and strategic investors.
|year||authors and title||journal||last update|
Marzia Rossato, Alsya J. Affandi, Soley Thordardottir, Catharina G. K. Wichers, Marta Cossu, Jasper C. A. Broen, Frederique M. Moret, Lara Bossini-Castillo, Eleni Chouri, Lenny van Bon, Femke Wolters, Wioleta Marut, Maarten van der Kroef, Sandra Silva-Cardoso, Cornelis P. J. Bekker, Harry Dolstra, Jacob M. van Laar, Javier Martin, Joel A. G. van Roon, Kris A. Reedquist, Lorenzo Beretta, Timothy R.
Association of MicroRNA-618 Expression With Altered Frequency and Activation of Plasmacytoid Dendritic Cells in Patients With Systemic Sclerosis
published pages: 1891-1902, ISSN: 2326-5191, DOI: 10.1002/art.40163
|Arthritis & Rheumatology 69/9||2019-07-26|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIRASYS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MIRASYS" are provided by the European Opendata Portal: CORDIS opendata.